Iaso

Epilepsy Foundation Partners with Iaso Ventures to Launch the NeuroImpact Fund

Retrieved on: 
Wednesday, March 20, 2024
Epilepsy, Caregiver, Partnership, Iaso, Research, History, Epilepsy Foundation, Therapy, Pharmaceutical industry

BOWIE, Md., March 20, 2024 /PRNewswire/ -- Today, the Epilepsy Foundation announced a transformative partnership with Iaso Ventures, a prominent venture capital firm, to establish the Iaso NeuroImpact Fund. This innovative fund serves as a cornerstone for advancing the development of pioneering therapeutics, diagnostics, and technologies aimed at revolutionizing the landscape of care for epilepsy and seizure disorders. Leveraging the professional investment acumen of Iaso Ventures and the profound research and clinical expertise of the Epilepsy Foundation, the NeuroImpact Fund is poised to catalyze breakthroughs in epilepsy treatment and support.

Key Points: 
  • Venture Philanthropy Fund to Support Development of New Therapeutics, Diagnostics and Technologies
    BOWIE, Md., March 20, 2024 /PRNewswire/ -- Today, the Epilepsy Foundation announced a transformative partnership with Iaso Ventures, a prominent venture capital firm, to establish the Iaso NeuroImpact Fund.
  • Leveraging the professional investment acumen of Iaso Ventures and the profound research and clinical expertise of the Epilepsy Foundation, the NeuroImpact Fund is poised to catalyze breakthroughs in epilepsy treatment and support.
  • "Throughout history, the Epilepsy Foundation has been at the forefront of supporting early-stage companies developing innovative solutions for epilepsy," said Bernice Martin Lee, chief executive officer, Epilepsy Foundation.
  • Companies funded through the Iaso NeuroImpact Fund hold the promise to redefine epilepsy treatment paradigms with the most cutting-edge approaches.

IASO Biotherapeutics Application for Clinical Trials of the Second Indication of its Fully Human CD19/CD22 Dual-targeted CAR-T Drug Accepted by NMPA

Retrieved on: 
Monday, June 7, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Health sciences, Medicine, Clinical medicine, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Leukemia, Lymphoma, Therapy, Iaso, CT120：, Non-Hodgkin Lymphoma (NHL):, IASO Biotherapeutics, CT120：, NON-HODGKIN LYMPHOMA (NHL):, IASO BIOTHERAPEUTICS

These successful clinical trial applications highlight the companys speed and strength in developing innovative novel CAR-T therapies.

Key Points: 
  • These successful clinical trial applications highlight the companys speed and strength in developing innovative novel CAR-T therapies.
  • CT120 is developed on IASO Bios fully human antibody platform IMARS and high throughput CAR-T drug selection platform.
  • Therefore, the therapy shows promise in terms of both market landscape and patient benefits, said Dr. Wang Wen, CEO, IASO Biotherapeutics.
  • At IASO Biotherapeutics, we will continue to expand and exploit new product pipelines to benefit more patients in the future.

WellsCare signs in-store contract with b8ta for IASO

Retrieved on: 
Sunday, September 20, 2020
B8ta, Lowe's, Macy's, Epione, Iaso

SEOUL, South Korea, Sept. 20, 2020 /PRNewswire/ -- WellsCare , a member company of the Born2Global Centre , recently signed a store contract with b8ta , a famous American flagship store that is dedicated to innovative products.

Key Points: 
  • SEOUL, South Korea, Sept. 20, 2020 /PRNewswire/ -- WellsCare , a member company of the Born2Global Centre , recently signed a store contract with b8ta , a famous American flagship store that is dedicated to innovative products.
  • Based on the contract, WellsCare will be selling IASO , its hands-free wearable cold laser pain relief device, at all 18 b8ta locations in the United States.
  • Starting in October with the New York, San Francisco, Texas, and Seattle stores, IASO will be made available sequentially in stores throughout the country.
  • IASO is the global brand of Epione, a wearable smart LoT laser therapy device developed independently by WellsCare.

WellsCare to target Middle Eastern market for its homecare laser pain treatment device

Retrieved on: 
Thursday, July 2, 2020
Epione, Iaso, Sharaf

IASO is the global brand of Epione, a wearable laser pain treatment device that was developed by WellsCare.

Key Points: 
  • IASO is the global brand of Epione, a wearable laser pain treatment device that was developed by WellsCare.
  • IASO is a homecare medical device that enables the treatment of diverse painful conditions, such as visual display terminals syndrome (caused by excessive PC/smart phone use) and everyday/sports-related pain (etc.)
  • WellsCare CEO Lee Sung-won said, "Our initial foothold in the Middle Eastern market was made possible when Sharaf DG contacted us directly.
  • Headquartered in Seoul, South Korea, WellsCare aims to lead the smart health device market with its advanced technology and innovation.